SCHEDULE: Ameriprise Financial Discloses Pasithea Therapeutics Stake

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have filed a Schedule 13G, reporting beneficial ownership of 5.4% of Pasithea Therapeutics Corp. common stock as of March 31, 2026.

Summary

• Ameriprise Financial, Inc. (AFI) and its subsidiary Columbia Management Investment Advisers, LLC (CMIA) have filed an amendment to their Schedule 13G.
• The filing indicates that as of March 31, 2026, CMIA beneficially owns 1,350,896 shares of Pasithea Therapeutics Corp. common stock.
• This represents 5.4% of the class of securities.
• AFI, as the parent company of CMIA, may be deemed to beneficially own these shares.
• Both AFI and CMIA disclaim beneficial ownership of any shares reported on this Schedule, suggesting they hold these shares in a fiduciary or investment management capacity.
• The filing is made under Rule 13d-1(b), indicating that the reporting persons are investment advisers.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It indicates institutional interest but lacks specific performance data or strategic insights about Pasithea Therapeutics Corp. itself.

Positives

• Significant institutional ownership by Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC, indicating confidence in the company's long-term prospects.
• The reporting persons are investment advisers, suggesting a professional and strategic approach to their investment in Pasithea Therapeutics Corp.

Negatives

• The disclaimer of beneficial ownership by both AFI and CMIA suggests that these shares are held in a fiduciary capacity and may not represent a strategic control interest by Ameriprise.
• The filing does not provide details on the specific investment strategy or the rationale behind acquiring this stake.

Risks

• Potential for future sales of shares by Ameriprise Financial, Inc. or Columbia Management Investment Advisers, LLC, which could impact the stock price.
• The filing does not disclose any specific risks related to Pasithea Therapeutics Corp. itself, as it is a disclosure of ownership by an investor.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Pasithea Therapeutics Corp. It solely reports on the ownership stake of Ameriprise Financial and its subsidiary.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors acquiring a significant, but non-controlling, stake in a public company. This filing indicates that Ameriprise Financial, through its investment management arm, has taken a notable position in Pasithea Therapeutics Corp., a company operating in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, potentially signaling confidence in the company. However, the disclaimer of beneficial ownership suggests this may not translate to active influence.
• Management: The filing does not directly impact management unless it leads to increased scrutiny or engagement from the institutional investor.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Monitor future filings by Ameriprise Financial and Pasithea Therapeutics Corp. for any changes in ownership or strategic developments.
• Analyze Pasithea Therapeutics Corp.'s own financial reports and business updates to understand the underlying value of the investment.

Key Dates

Keywords

Schedule 13G, Pasithea Therapeutics Corp, Ameriprise Financial, Columbia Management Investment Advisers, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Adviser